文献速递肝病

富马酸替诺福韦二吡呋酯与恩替卡韦治疗慢性HBV感染患者的肾功能变化

Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-08-18

回顾性研究比较富马酸替诺福韦二吡呋酯(TDF,n=239)与恩替卡韦(n=171)治疗慢性HBV感染患者,平均随访43-46个月。倾向评分匹配后eGFR≥60队列中两药调整平均eGFR相似;但在eGFR<60队列及未匹配总体中TDF组调整平均eGFR显著更低(均P<.001)。结论:无显著肾损害患者中TDF未增加中短期肾功能恶化风险,基线肾损害患者中TDF组肾下降更显著。

要点

  • eGFR≥60匹配队列中TDF与恩替卡韦调整平均eGFR相似。
  • 未匹配总体及eGFR<60队列中TDF组调整平均eGFR显著更低(均P<.001)。
  • Cox回归中TDF与恩替卡韦相比未增加轻中度肾损害风险。

核心结论

  • 在无显著肾损害的慢性HBV感染患者中,TDF与恩替卡韦相比未增加中短期随访期间肾功能恶化风险。
  • 基线肾损害患者中,与恩替卡韦组相比,TDF组出现显著肾下降。
  • 因慢性HBV治疗通常长期或终身,需要随访时间更长的额外研究。

研究设计与样本

  • 回顾性研究,纳入2000年至2016年接受TDF(n=239)或恩替卡韦(n=171)治疗的慢性HBV感染患者,平均随访43-46个月。
  • 血清肌酐在治疗期间测量≥12个月;患者无既往阿德福韦暴露,无HCV、HDV或HIV合并感染。
  • 对年龄、性别、高血压、糖尿病、基线eGFR、肝硬化和随访时长进行倾向评分匹配(PSM)。
  • 采用多变量广义线性模型(调整肝硬化、糖尿病、高血压)估计匹配与未匹配队列的调整平均eGFR;Cox回归识别肾损害预测因素。

主要发现

  • PSM后eGFR≥60者中,恩替卡韦组116例,TDF组116例;eGFR<60者中,恩替卡韦组32例,TDF组26例。
  • 未匹配总体队列及eGFR<60队列的多变量广义线性模型显示,TDF组调整平均eGFR显著更低(均P<.001)。
  • eGFR≥60的PSM队列中,接受两种治疗的患者调整平均eGFR相似。
  • Cox回归分析中,与恩替卡韦相比,TDF与轻或中度肾损害无关联。

局限性

  • 原文为回顾性研究。
  • 随访时间短或中等,原文指出因慢性HBV治疗通常长期或终身,需要随访时间更长的额外研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is unclear whether drugs used to treat chronic hepatitis B virus (HBV) infection cause significant renal impairment. We compare adjusted mean estimated glomerular filtration rates (eGFR; mL/min/1.73 m2) of patients with chronic HBV infection treated with tenofovir disoproxil fumarate (TDF) vs patients treated with entecavir. METHODS: We performed a retrospective study of patients with chronic HBV infections treated with TDF (n = 239) or entecavir (n = 171), from 2000 through 2016, followed for a mean time of 43-46 months. Levels of serum creatinine were measured ≥12 months while patients received treatment. Patients did not have prior exposure to adefovir or HCV, HDV, or HIV co-infection. We performed propensity score matching (PSM) for age, sex, presence of hypertension, diabetes mellitus, baseline eGFR, cirrhosis, and follow-up duration. We performed multivariate generalized linear modeling, adjusting for cirrhosis, diabetes, and hypertension, to estimate adjusted mean eGFR for matched and unmatched cohorts. Cox regression was used to identify predictors of renal impairment. RESULTS: eGFRs were ≥60, after PSM, in 116 patients given entecavir and in 116 patients given TDF; eGFRs were <60 in 32 patients given entecavir and 26 patients given TDF. Multivariate generalized linear modeling of the unmatched overall and <60 eGFR cohorts revealed significantly lower adjusted mean eGFRs in patients given TDF (all P < .001). However, in the eGFR ≥60 PSM cohort, the adjusted mean eGFR was similar between patients receiving either treatment. In Cox regression analysis, TDF was not associated with mild or moderate renal impairment compared with entecavir. CONCLUSION: In a retrospective study of patients with chronic HBV infections treated with TDF vs entecavir, we found that TDF was not associated with higher risk of worsening renal function during short- or intermediate-term follow-up periods, among patients without significant renal impairment. Additional studies, with longer follow-up periods, are needed because treatment for chronic HBV infection is generally long term or life-long. For patients with baseline renal impairment, significant renal decline was among patients given TDF compared to patients given entecavir.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Trinh S, Le AK, Chang ET, et al. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. Clin Gastroenterol Hepatol. 2018. PMID: 30130625. doi:10.1016/j.cgh.2018.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。